It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The order strengthens the company’s position in the East African market
The pharma park will be built at an estimated cost of Rs 34.94 crore and will be spread over 50 acres at Chanho close to Ranchi
The National Health Authority (NHA) aims to deliver 10 crore Ayushman Bharat cards in this financial year and extend free hospitalization benefits to 50 lakh people in a quarter
Ibuprofen and Famotidine tablets (Duexise) had estimated annual sales of US $ 765 million in the US as if July 21
_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
_256_384.jpg)
ICMR receives conditional exemption from Drone Rules 2021 to speed up vaccine delivery in the A&N Islands, Manipur and Nagaland
Subscribe To Our Newsletter & Stay Updated
